Results 1 to 10 of about 3,487 (207)

Comparative Analysis of Choroid Plexus Volume Between MOG Antibody Associated Disease and Multiple Sclerosis. [PDF]

Ann Clin Transl Neurol
ABSTRACT Choroid plexus volume (CPV) has been proposed as a neuro‐immunological marker of multiple sclerosis (MS), but its relevance in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) remains uncertain. We analyzed CPV in 43 individuals with MOGAD, 48 with MS, and 44 healthy controls using a Bayesian Gaussian mixture modeling ...
Hyun JW, Hong SG, Park NY, Kim SH, Kim HJ.   +4 more
europepmc   +2 more sources

Quantitative MRI Uncovers Subtle Cortical Damage in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective To determine whether myelin‐sensitive quantitative MRI reveals microstructural abnormalities in normal‐appearing cortex (NACtx) in myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), indicating that conventional MRI underestimates remission residual cortical injury.
Camera V, Tamanti A, Messina S, Dall'Osto N, Maltempo T, Ziccardi S, Foschi M, Piscaglia MG, Ferraro D, Crescenzo F, Rossi F, Bajrami A, Marangoni S, Marastoni D, Pizzini FB, Leite MI, Magliozzi R, Waters P, Calabrese M, Palace J, Geraldes R.   +20 more
europepmc   +2 more sources

"Low-Positive" MOG-IgG Cases Among Adults With a First Event Suggestive of Multiple Sclerosis. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective To determine the prevalence and clinical characteristics of patients with “low‐positive” (LP) MOG‐IgG (titres 1:160–1:320) among adults with a first demyelinating event (FDE) suggestive of multiple sclerosis (MS). Methods From the Barcelona CIS inception cohort, we included adult patients with serum collected ≤ 6 months from the FDE.
Villacieros-Álvarez J, Espejo C, Arrambide G, Castillo M, Rodriguez M, Ariño H, Elosua I, Tur C, Vidal-Jordana A, Vilaseca A, Castilló J, Galán I, Midaglia L, Nos C, Rodríguez-Acevedo B, Zabalza A, Bollo L, Pappolla A, Carvajal R, Mongay-Ochoa N, Rio J, Sastre-Garriga J, Comabella M, Busiello G, Sceppacuercia S, Rovira À, Montalban X, Tintoré M, Auger C, Cobo-Calvo Á.   +29 more
europepmc   +2 more sources

Biomarkers for myelin oligodendrocyte glycoprotein-associated disease: recent advances and future [PDF]

Frontiers in Immunology
MOGAD is a rare autoimmune encephalomyelitis that shares similar clinical manifestations with other central nervous system demyelinating diseases. However, they must be distinguished due to their distinct pathogenesis and treatment methods.
Qingying Zheng, Qingying Zheng, Muzi Wen, Muzi Wen, Xinyi Zheng, Xinyi Zheng, Linxin Wen, Linxin Wen, Ruogu Cheng, Ruogu Cheng, Ye Gao, Ye Gao, Chao Yuan, Pei Shang, Pei Shang   +14 more
doaj   +2 more sources

Frequency and Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Accompanied by Fever: A Single-Center Retrospective Study. [PDF]

CNS Neurosci Ther
Diagnostic pitfall in fever with CNS involvement: MOGAD. Fever accompanied by neurological symptoms was initially suspected as central nervous system infection. However, negative pathogen tests and failed anti‐infective therapy, followed by positive MOG‐IgG, led to a revised diagnosis of MOGAD. The patient responded favorably to corticosteroids or IVIG.
Guo A, Shi FD, Shi K.
europepmc   +2 more sources

The Impact of COVID-19 Infection and Vaccination on Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody Disease: A Narrative Review [PDF]

Journal of Central Nervous System Disease
Despite the estimated 776 million coronavirus disease 2019 (COVID-19) cases globally, little is known about its impact on immune-mediated neurological disorders such as neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte ...
Jeffrey Hernandez DNP, APRN, Silvia Delgado MD, FAAN, Micheline McCarthy MD, PhD, Flavia Nelson MD, Kottil Rammohan MD   +4 more
doaj   +2 more sources

MOGAD Involving Cranial Neuropathies: A Case Report and Review of Literature

Brain Sciences, 2022
Myelin-oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an autoimmune-mediated demyelinating disease of the central nervous system (CNS). Patients with MOGAD may develop any combination of optic neuritis (ON), myelitis, brainstem
Kailing Huang, Ling Xiao
exaly   +3 more sources

Clinical and Modifiable Factors Associated With Disability and Relapse in MOGAD: A Multicentre Cohort Study. [PDF]

Ann Clin Transl Neurol
ABSTRACT Background Factors associated with relapse course and disability in myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) remain incompletely understood. Objectives To identify clinical and modifiable factors associated with relapse and disability in MOGAD. Methods In this ambispective multicentre cohort study using data from
Wang Y, Tao S, Wang Q, Xu X, Yao H, Liu Z, Li D, Qiu Z, Han J, Xia J, Wang Q, Sun J, Shao K, Li J, Ruan S, Zhong Y, Guo J, Guo S, Huang Y, Chai G, Jin T, Zhou H, Hao J, Zhao Y.   +23 more
europepmc   +2 more sources

Evaluation of Dried Plasma Spot-Based Quantification of Glial Fibrillary Acidic Protein as a Disease-Associated Biomarker in Neuromyelitis Optica Spectrum Disorder. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective To evaluate the diagnostic accuracy of glial fibrillary acidic protein (GFAP) measured in dried plasma spots versus conventional plasma‐ and serum‐GFAP testing for assessment of disease severity in aquaporin‐4 immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD).
Wohlrab F, Alvarez E, Hamdi R, Zhang B, Ji H, Jhaveri N, Schindler P, Sanchez P, Sperber PS, Schmitz-Hübsch T, Oertel FC, Vorasoot N, Kissani N, Böhringer F, Kuhle J, Pröbstel AK, Ma XJ, Körtvelyessy P, Waters P, Paul F.   +19 more
europepmc   +2 more sources

MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objectives The study aimed to characterize the clinical features, etiologies, and outcomes of isolated, first‐time pediatric ON in the post‐MOG‐IgG era. Methods This was a single‐center retrospective cohort study at Texas Children's Hospital of patients diagnosed with first‐time ON between 2018–2024, with follow‐up data collected through 2025.
Aduru C, Chandrasekar A, Blasingame K, Rosen J, Levine JM, Salazar K, Chilakapati M, Foroozan R, Hardwick V, Yarimi JM, Shukla N, Lotze TE, Fisher KS, Sandweiss AJ.   +13 more
europepmc   +2 more sources